论文部分内容阅读
目的:研究分析糜烂溃疡性口腔黏膜病应用复方曲安奈德联合金因肽治疗的临床疗效。方法:选取2014年1月至2017年1月期间在我院接受治疗的120例糜烂溃疡性口腔黏膜病患者作为研究对象。以治疗方式为依据,将患者分成对照组与观察组,每组各60例。其中,对照组给予利凡诺治疗,观察组给予复方曲安奈德联合金因肽治疗。结果:观察组REU评分为(0.37±2.11),明显对于对照组评分(1.73±3.62);观察组VAS评分为(1.07±2.13),明显对于对照组评分(3.23±2.12);观察组患者伤口愈合时间为(6.51±3.15)d,明显优于对照组患者伤口愈合在时间(9.51±2.13)d。观察组患者治疗有效率为95%,明显高于对照组患者治疗有效率75%。结论:复方曲安奈德联合金因肽治疗糜烂溃疡性口腔黏膜病效果更显著,值得临床推广。
Objective: To study the clinical efficacy of compound triamcinolone acetonide combined with gold peptide in the treatment of erosive and ulcerative oral mucosal diseases. Methods: From January 2014 to January 2017 in our hospital for treatment of 120 cases of erosion ulcerative oral mucosal disease patients as the research object. Based on the treatment method, the patients were divided into control group and observation group, 60 cases in each group. Among them, the control group was given rivanol treatment, the observation group was given compound triamcinolone acetonide treatment. Results: The score of REU in the observation group was (0.37 ± 2.11), significantly higher than that of the control group (1.73 ± 3.62). The VAS score of the observation group was (1.07 ± 2.13), significantly higher than that of the control group (3.23 ± 2.12) The healing time was (6.51 ± 3.15) days, which was significantly better than that of the control group (9.51 ± 2.13 days). Observation group of patients with treatment efficiency was 95%, significantly higher than the control group, the effective rate of 75%. Conclusion: Compound triamcinolone acetonide combined with gold peptide in the treatment of erosive ulcerative oral mucosal disease is more effective and worthy of clinical promotion.